Growth signals Materialise reports Q2 2026 revenue growth of 8% year over year to €70.1 million with improving profitability and an increased adjusted EBIT outlook, indicating a strengthening financial position that supports for expanding partnerships in medical device software and services.

Medical leadership As a global leader in 3D-printed medical devices and software, Materialise continues to drive end-to-end solutions for healthcare, creating opportunities to upsell advanced additive manufacturing software, consulting, and manufacturing services to hospitals and device manufacturers.

Strategic divestitures The company is divesting rapid prototyping and eyewear businesses, signaling a strategic shift toward core healthcare and manufacturing software solutions, which presents opportunities to target customers seeking integrated, risk-managed 3D printing platforms.

Global expansion Materialise operates with over 30 years of experience and serves multiple industries worldwide, presenting cross-sell potential into new geographic regions and adjacent verticals like industrial manufacturing and personalized healthcare workflows.

Tech stack leverage With a modern tech stack including Azure, Salesforce Service Cloud, and collaboration tools, there is potential to offer integration services, data analytics, and managed cloud-based solutions that enhance existing customers’ additive manufacturing ecosystems.